RIGL peer analysis
Rigel Pharmaceuticals (RIGL) against its competitors: price, today's move, 1-year return and market value side by side.
RIGL and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ALXO ALX Oncology | $1.36 | 5.43% | -13.38% | – |
| ANL Adlai Nortye | $9.63 | 0.52% | 592.81% | – |
| CCCC C4 Therapeutics | $3.12 | -2.96% | 25.60% | – |
| CGEM Cullinan Therapeutics | $12.50 | -20.63% | 60.05% | – |
| CRDF Cardiff Oncology | $0.86 | 2.23% | -62.64% | $67.15M |
| CRIS Curis | $0.86 | 20.80% | -97.09% | $1.73M |
| EXEL Exelixis | $72.78 | 0.65% | 91.22% | $17.64B |
| MREO Mereo BioPharma | $0.29 | 0.34% | -84.35% | $46.47M |
| NRIX Nurix Therapeutics | $15.82 | -38.73% | 25.36% | – |
| VSTM Verastem | $9.87 | 0.97% | -0.35% | $1.19B |
| RIGL Rigel Pharmaceuticals | $51.26 | 4.91% | 67.24% | $912.70M |
- RIGL's peers: ALXO (ALX Oncology), ANL (Adlai Nortye), CCCC (C4 Therapeutics), CGEM (Cullinan Therapeutics), CRDF (Cardiff Oncology), CRIS (Curis), EXEL (Exelixis), MREO (Mereo BioPharma).
Updated 2026-11-05 12:49 UTC